• 论坛首页
  • 我的丁香客
  • 找人
    查找好友
  • 更多
    丁香园
    丁香通
    丁香人才
    丁香会议
    丁香搜索
    丁香医生
    丁香无线
    丁香导航
    丁当铺
    文献求助
    医药数据库
    丁香诊所
    来问医生
登录 注册

知识产权

关注今日:0 | 主题:25453
论坛首页  >  医药知识产权讨论版   >  案例分析
  • 发帖
    每发1个新帖
    可以获得0.5个丁当奖励
  • 回帖

分享到:

  • 微信

    微信扫一扫

  • 微博
  • 丁香客
  • 复制网址

默克 Keytruda 的专利纠纷案

  • 只看楼主
  • 页码直达:
  • 直达末页
楼主 freelane
freelane
铁杆站友

  • 515
    积分
  • 3844
    得票
  • 1.2万
    丁当
  • 1楼

Anatomy of a billion dollar patent drug dispute - the Merck Keytruda patent

February 23 2018
https://www.ambercite.com/amberblog/2018/2/23/keytruda-patent-analysis  原文链接


Keytruda, the Merck brand name for pembrolizumab, is a humanized antibody used in cancer treatment. According to Reuters, Keytruda bought in more than $1 billion in sales in the third quarter of 2017, and is expected to generate peak annual sales of USD8.2 billion in 2020. No wonder then, that a recent positive trial report was enough to increase the value of Merck shares by 6%.

Pembrolizumab was first invented by three scientists at the Dutch pharma company Organon, which was purchased by Schering-Plough, in turn acquired by Merck, who according to Wikipedia were at one stage preparing to outlicense the drug, before its potential was recognised. Since then its use has moved from melanoma to other cancers, even if at a cost to patients of up to $150,000 per year.

Not surprisingly, there has been patent litigation this area. Back in January 2017, Merck announced a settlement with Bristol-Myers Squibb and Ono Pharamceutical, that included an upfront payment of USD625 million, and royalties of 6.5% or 2.5% of sales. 

This patent dispute has been reviewed by Mathieu Collin of INSERM, who noted that was in relation to the Bristol Myers Squib patent family that included US8779105 Monoclonal antibodies to programmed death 1 (PD-1)   (priority date of May 2005), while the Pembrolizumab patent family corresponding to US8354509   Antibodies to human programmed death receptor PD-1  (priority date of June 2007).

Ambercite has developed both graphical and list based tool to analyse patent families and their relationships with other patent families - so what Ambercite show in this case?

Amberscope analysis 

For the Amberscope analysis, we might start with the Bristol Myers Squibb patent.

The Amberscope image below shows the direct patent network family for US8779105 (the patent number shown in the details box is US8008449 - the first granted US family member for this patent family).

There are a few points to note in this image. First of all, this network is very packed - our data suggests that 313 different patent families cite this Bristol Myers patent families, while 142 separate patent families have been cited against it. This area is clearly commercially important. Not surprisingly, this has led to a very high value of the Ambercite patent value predictor Amberscore - this value is 28, compared to the average value of 1 for Amberscore against all patent families in our database. 

While descriptive, this network is almost too packed to work with. Luckily. Amberscope comes with some tools that can simplify networks, and in the image below our priority date filter has been set so that only patents with priority date of 2005 and later are shown, and our Similarity filter has been set so that only the 10% most similar patents are shown (see the small orange segment).


Of note, one of the three remaining patents after this analysis is US8354509, the (now owned by Merck) pembrolizumab patent. This has an Amberscore value of 6.5 - still much higher than average, but not as high as the Bristol Myers Squibb patent.

If we look carefully at the details box for US8354509, there is a button that says '30 more'. This means that if we press this button, Amberscope will refocus the network onto this patent, and there will be 30 additional patents not found in the network for the Bristol Myers Squibb patent.

And this refocussed patent network looks like this - also a very packed network, suggesting  high patent value.

Ambercite analysis of the pembrolizumab patent

Ambercite allows you to do a similar analysis in table form. If we start from the pembrolizumab patent in this case, and ask for the 5 most similar patents, the resulting list looks like this:

And in fact, we could choose to display the most similar 10, 50..up to the most similar 2000 patents if we wished, and then apply a series of filters on the results. 

But in this case, the 5 most similar patents is enough, particularly at the top of this list is US8008449B2 - or the first granted US family member to the US8779105 Bristol Myers Squibb patent that Merck have agreed to license. 

 

The value of Ambercite Similarity scores

If we look at the third column in the table above, this shows a list of "Similarity Scores". This shows value trending down from 181 for the Bristol Myers Squibb patent family - and the higher the value, the most similar the patents found by Ambercite. 181 is a very high score for similarity.

Similarity scores are a key benefit of Ambercite. Conventional citation analysis is often based on individual patents, and in the case of US8779105 would provide a list of 325 forward citations, at least on 23 February 2018. Ok, there is plenty of information - but where do you start?

In contrast, with the Ambercite analysis, it is clear that you should start with the pembrolizumab patent - the patent that leads you to the very lucrative payday that Bristol Myers Squibb had last year. 


  • 邀请讨论
  • 不知道邀请谁?试试他们

    换一换
2019-06-29 10:01 浏览 : 4535 回复 : 1
  • 投票
  • 收藏 1
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
freelane 编辑于 2019-06-29 10:04
  • • 【规培笔记128】—工作报告偶遇,颅脑MR,您能看出几处异常?据说工作中很罕见!
楼主 freelane
freelane
铁杆站友

  • 515
    积分
  • 3844
    得票
  • 1.2万
    丁当
  • 2楼

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

Merck & Co has agreed terms to bring a patent dispute centred on its cancer immunotherapy Keytruda to an end.

The US drugmaker has agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625m to settle the patent infringement litigation - focusing on intellectual property in the area of PD-1 inhibitors - and will also pay a 6.5% royalty on sales of Keytruda (pembrolizumab) through to December 2023. A lower 2.5% royalty rate applies from January 2024 to December 2026.

The deal lays to rest any lingering risk of an interruption in Keytruda supply for patients and results in dismissal of all patent litigation filed against Merck by BMS and Ono. It is also an important result for BMS, which has had a run of ill news with Opdivo of late with Keytruda claiming a competitive advantage in key indications such as non-small cell lung cancer (NSCLC).

The upfront payment and royalties could amount to a fairly sizeable sum - assuming Keytruda meets expectations of becoming a $6bn-plus product by 2022 that would equate to $390m or more in that year alone. The initial payment and royalties will be shared between Ono and BMS with the Japanese firm getting a quarter share and BMS pocketing the remainder.

BMS and Ono filed suit against Merck shortly after Keytruda became the first drug to be approved in the US in September 2014, claiming Merck's drug contravened a US patent covering the use of antibodies which bind to the PD-1 drug target in the US, some EU countries, Australia and Japan.

BMS and Ono were first to market with their Opdivo (nivolumab) PD-1 inhibitor, claiming approval in Japan in July of that year and launching it in September.

Merck's chief executive Kenneth Frazier said the deal "eliminates uncertainty and enables us to continue to focus on Keytruda… which is already helping thousands of patients around the world and becoming a foundation for the treatment of cancer through our industry-leading clinical development programme".

Frazier's counterpart at BMS, Giovanni Caforio, said the settlement "validates the strong intellectual property rights we secured as the early innovators in the science of PD-1".

It is also "a good decision for patients as it supports the continuation of ongoing research and maintains access to anti-PD-1 therapies for cancer patients around the world," added Caforio.


2019-06-29 10:05
  • 投票 1
  • 收藏
  • 打赏
  • 引用
  • 分享
    • 微信扫一扫

    • 新浪微博
    • 丁香客
    • 复制网址
  • 举报
    • 广告宣传推广
    • 政治敏感、违法虚假信息
    • 恶意灌水、重复发帖
    • 违规侵权、站友争执
    • 附件异常、链接失效
    • 其他
  • • 死亡患者危重讨论怎么写?

关闭提示

需要2个丁当

丁香园旗下网站

  • 丁香园
  • 用药助手
  • 丁香通
  • 文献求助
  • 丁香人才
  • 丁香医生
  • 丁香导航
  • 丁香会议
  • 手机丁香园
  • 医药数据库

关于丁香园

  • 关于我们
  • 丁香园标志
  • 友情链接
  • 联系我们
  • 加盟丁香园
  • 版权声明
  • 资格证书

官方链接

  • 丁香志
  • 丁香园新浪微博
引用回复